CRIS Current Research Information System

BARTOLETTI, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.381
NA - Nord America 1.255
EU - Europa 768
AF - Africa 91
SA - Sud America 69
OC - Oceania 3
Totale 3.567
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.226
SG - Singapore 417
VN - Vietnam 349
CN - Cina 330
IT - Italia 138
DE - Germania 121
SE - Svezia 118
GB - Regno Unito 97
HK - Hong Kong 72
IN - India 70
FR - Francia 58
BR - Brasile 49
IE - Irlanda 45
RU - Federazione Russa 43
FI - Finlandia 36
NL - Olanda 36
CI - Costa d'Avorio 35
KR - Corea 34
TG - Togo 22
JP - Giappone 18
CA - Canada 17
ZA - Sudafrica 12
CH - Svizzera 11
ID - Indonesia 11
PL - Polonia 11
JO - Giordania 10
PH - Filippine 10
TH - Thailandia 10
BE - Belgio 9
TR - Turchia 9
TW - Taiwan 9
UA - Ucraina 9
BD - Bangladesh 8
AT - Austria 7
BG - Bulgaria 7
MX - Messico 6
AR - Argentina 5
CO - Colombia 5
EC - Ecuador 5
EE - Estonia 5
PK - Pakistan 5
NG - Nigeria 4
SA - Arabia Saudita 4
TN - Tunisia 4
AU - Australia 3
ET - Etiopia 3
HR - Croazia 3
IQ - Iraq 3
MA - Marocco 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ES - Italia 2
JM - Giamaica 2
LT - Lituania 2
RO - Romania 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GF - Guiana Francese 1
HU - Ungheria 1
KE - Kenya 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MG - Madagascar 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 3.567
Salva come PNG Salva come JPEG
Città #
Singapore 309
Ashburn 172
Chandler 121
San Jose 101
Hanoi 89
Ho Chi Minh City 77
Southend 69
Hong Kong 65
Fairfield 64
Hefei 54
Santa Clara 53
Dublin 45
Beijing 44
Dallas 40
Princeton 38
Abidjan 35
Dong Ket 32
Los Angeles 31
Helsinki 29
Woodbridge 29
Houston 28
Seoul 27
Boardman 26
Bologna 26
Seattle 25
Wilmington 25
Council Bluffs 24
Cambridge 22
Lomé 22
Hyderabad 21
Milan 21
Munich 21
New York 21
Lauterbourg 20
Ann Arbor 17
Redmond 15
Nanjing 14
Frankfurt am Main 13
Tokyo 13
Bremen 12
Buffalo 12
Da Nang 12
Berlin 11
Amman 10
Westminster 10
Brussels 9
Haiphong 9
Bern 8
Chicago 8
London 8
Nuremberg 8
Shanghai 8
Turin 8
Warsaw 8
Des Moines 7
Jakarta 7
Johannesburg 7
Sofia 7
Toronto 7
Guangzhou 6
Orem 6
Phoenix 6
Redondo Beach 6
San Francisco 6
Shenyang 6
São Paulo 6
Amsterdam 5
Bengaluru 5
Boydton 5
City of London 5
Lappeenranta 5
Paris 5
Redwood City 5
Saint Petersburg 5
San Diego 5
Abeokuta 4
Biên Hòa 4
Brooklyn 4
Bình Phước 4
Changchun 4
Hải Dương 4
Migliarino 4
Norwalk 4
Rome 4
Shijiazhuang 4
Stockholm 4
The Dalles 4
Vienna 4
Wayne 4
Wenzhou 4
Addis Ababa 3
Bari 3
Can Tho 3
Chennai 3
Dhaka 3
Ercolano 3
Falkenstein 3
Fuzhou 3
Hangzhou 3
Jinan 3
Totale 2.251
Salva come PNG Salva come JPEG
Nome #
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 227
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 220
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 213
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 193
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 175
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 154
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 154
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 151
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 143
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 142
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 138
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 135
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 135
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 132
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 128
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 127
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 125
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 118
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 116
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 107
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 105
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 101
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 94
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 91
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 86
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 83
null 68
Totale 3.661
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.694
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.694
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202170 0 0 0 0 0 0 0 0 0 4 9 57
2021/2022349 5 13 13 33 25 18 8 32 16 31 91 64
2022/2023478 35 58 30 63 44 48 12 28 97 14 26 23
2023/2024173 9 38 18 18 14 22 2 14 4 15 8 11
2024/2025667 59 59 59 64 70 34 42 48 8 63 43 118
2025/20261.565 149 122 150 119 164 94 161 99 387 120 0 0
Totale 3.661